Empowering the Voice of Kansas Pharmacy

Log in
 
 
It's time to RECONNECT with your Kansas Pharmily - IN-PERSON!

REGISTER TODAY!

POSTER PRESENTATIONS

Gear up for the 2021 KPhA Annual Meeting with the VIRTUAL POSTER SESSION

highlighting research by University of Kansas School of Pharmacy students.

Name: Christine Rogers
School: KU School of Pharmacy

About: Christine is a PharmD candidate in the class of 2022. She is interested in perusing a position in sterile compounding or nuclear pharmacy.

Category: Original Research

Presentation Info
Date: Sunday, Sept. 19
Time: 2 p.m.


Title: Medication use evaluation of micafungin

Objective: To assess appropriateness of micafungin in the treatment of candida infections with respect to the local antibiogram.

Abstract: This medication use evaluation was conducted to assess appropriateness of micafungin in the treatment of candida infections with respect to the local antibiogram. Echinocandins are a first line option for a variety of candida infections per the Clinical Practice Guidelines for the Management of Candidiasis based on the class’s broad coverage of candida species. In the clinical setting echinocandins, like micafungin, are chosen other antifungal therapies to cover potentially resistant candida species. Resistant candida are becoming more prevalent therefore reserving the echinocandins for serious candida infections is vital for longevity of the drug. A chart review was conducted on patients admitted to Saint Luke’s Health System from March 29th, 2017 to May 28th, 2021 and receiving one or more doses of micafungin. Data collection included cultures, fungitell, therapy length, and de-escalation to fluconazole. The analysis included 983 patients who received micafungin for an average of 6.2 days. 32.8% of the patients with positive cultures and/or positive fungitell (232- cultures and 91-fungitell).67.2% of patients had no positive culture or positive fungitll and received micafungin treatment for an average of 9.9 days. A review of symptoms, signs of infection, drug indications and diagnosis were not included in the chart review. This medication use evaluation provides information on local resistance along with insight on the trend of prolonged echinocandin treatment in those without a documented infection. These data will be utilized to provide information to prescribers on use trends and further opportunities for antimicrobial stewardship.

Name: Yezan Salamoun
School: KU School of Pharmacy

About:Yezan is a PharmD candidate in the class of 2023. He is interested in industry and academia, and considering getting a PhD after Pharmacy school, most likely in Pharmaceutical Chemistry. He also is involved in an entrepreneurial endeavor and aspires to build his own company in the future.

Category: Original Research

Presentation Info
Date: Sunday, Sept. 19
Time: 2:20 p.m.


Title: Development of a Stability Indicating Assay for the Analysis of Unit-Dose Packaged Nitroglycerin Sublingual Tablets

Objective: The objective of this work was to develop a stability indicating assay for Nitroglycerin sublingual tablets to investigate stability under different forms of unit-dose packaging.

Abstract: Background: Nitroglycerin sublingual (NTG) tablets are only available in glass containers from the manufacturer, who recommend against their removal to prevent loss of tablet potency. Glass vials are problematic due to their inability to be stored in automated dispensing cabinets (ADC), thus are frequently misplaced causing inventory inaccuracies and increased costs. The stability of NTG in unit-dose packaging has not been previously studied. This work seeks to develop a stability indicating assay for NTG to investigate stability under different forms of unit-dose packaging. Methods: NTG verified analytical grade standard was used to develop an ultra-performance liquid chromatographic method with ultraviolet detection (UPLC-UV) method for the quantitation of NTG content in sublingual tablets. Forced degradation studies included the exposure of NTG tablets exposed to open air at 50°C for 43hrs. NTG potency was measured in tablets from Pfizer and Greenstone Labs stored in manufacture supplied vials, manual processed blister cards, and an automated packaging system. Preparations were protected from light, humidity, and temperature and monitored 3x weekly. Potency was assessed at 0, 30, and 62 days. Results: The NTG quantitative assay was found to be linear over a range of 25% to 125% potency (r2=0.9997) with an average coefficient of variation of 2.2%. Forced degradation of NTG tablets resulted in loss of 51.2±3.4% potency. Starting potency (i.e. Day 0), was found to be 100.0±3.2%. Potencies on Day 30: auto-pack; 91.9±3.9%, and manual pack; 40.6±3.4%. Potencies on Day 62: auto-pack; 79.0±3.0%, and manual pack; 25.6±2.1%. Conclusions: An automated packaging system, but not manual packaging, was able to maintain 90% potency for 30 days. Both systems failed to maintain a suitable potency after 62 days. A cost-analysis will be conducted to see if this packing is a feasible option for in-patient setting. Future testing on different auto-packing machines will be conducted.

Name: Meylinda Sari
School: KU School of Pharmacy

About: Meyinda is a PharmD candidate in the Class of 2023. Research during her first two years of pharmacy school centered in the Pharmaceutical Chemistry department, but as her intrests shifted, she now conducts research Pharmacy Practice department. Meylinda plans to join the residency program after graduation to gain additional knowledge in Pharmacy Practice.

Category: Original - Research Complete

Presentation Info
Date: Sunday, Sept. 19
Time: 2:40 p.m.


Title: Determination of Miltefosine Plasma Protein Binding Using Equilibrium Dialysis and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Objective: Miltefosine is an alkyl phosphocholine compound that is used primarily for treatment of leishmaniasis and has been used off-label to treat amoebic encephalitis. Recommendations for treatment of amoebic encephalitis generally include miltefosine therapy. It was previously reported that plasma protein binding of miltefosine ranges between 96% and 98%, with no concentration dependence being observed. Miltefosine binds to both serum albumin and lipo-proteins, with a preference for albumin (97% of the fraction bound) over low-density lipoprotein (3% of the fraction bound). Accurate determination of unbound drug fraction in plasma is important as only free drug molecules interact with the therapeutic target and unbound drug fraction is a key parameter in pharmacokinetic modeling to predict drug concentrations in plasma and tissues. In this study, we aim to determine unbound fraction of miltefosine in the mouse plasma using the Rapid Equilibrium Dialysis (RED) method. The RED is a rapid, accurate and reliable method to determine protein binding of drug molecules. The resulting samples are then analyzed by LC-MS/MS using Multiple Reaction Monitoring (MRM) on a triple quadrupole mass spectrometer, which is a highly specific and sensitive mass spectrometric technique for quantification of chemical compounds in complex matrix.

Abstract: Constructing the right method to determine protein binding is really important, especially for drugs that highly bind to protein like miltefosine. The a nity of miltefosine to protein determines the effectiveness of it. A small difference in protein binding can make a significant difference in therapy. In this study, RED and LC-MS methods were used to determine plasma protein binding of miltefosine in mouse. From the observed data, it can be concluded that miltefosine is highly bound to plasma proteins with >99% bound.

CONFERENCE SPONSORS

Gold Sponsors

Silver Sponsors

Additional Support

Abbvie Velocity Wealth Mgmt

Questions? Contact jen@ksrx.org to learn more.


KPhA appreciates the generous support provided by

Diamond Corporate Members
Silver Corporate Members
Bronze Corporate Members
Compliant Pharmacy Alliance
PBA Health
Pharmacists Mutual







Kansas Pharmacists
Association

Preserving, protecting and advancing Kansas pharmacy practice through education, engagement and advocacy.

Contact Us

  • 1020 SW Fairlawn Road
    Topeka, KS 66604
  • 785.228.2327
  • info@ksrx.org
Powered by Wild Apricot Membership Software